A study has shown that asthma patients may be switched from Seretide (fluticasone propionate-salmeterol [FP-SAL]) to Fostair (extra-fine beclomethasone-formoterol [efBDP-FOR]) at an equivalent or lower inhaled corticosteroid (ICS) dosage with no reduction in clinical effectiveness but a significant reduction in cost to the UK’s National Health Service (NHS).
Results from the REACH study, published in the Primary Care Respiratory Journal,investigated the clinical and cost effectiveness of switching typical asthma patients from London pharma major’s GlaxoSmithKline’s (LSE: GSK) Seretide to Fostair, made by privately-held Italian drugmaker Chiesi Farmaceutici. Results show that Fostair was non-inferior to Seretide and switching to Fostair resulted in significantly better odds of achieving overall asthma control and lower daily short-acting beta-2-agonist usage at a lower daily ICS dosage. It also reduced mean asthma-related health care costs by £93.63/patient/year ($154).
Fostair was launched in the UK by Chiesi in 2008, as a cheaper version of both Seretide and AstraZeneca’s Symbicort (budesonide/formoterol; The Pharma Letter January 28, 2008).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze